Brainstorm Cell Therapeutics Inc BCLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCLI is a good fit for your portfolio.
News
-
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
-
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
-
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
-
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
-
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
-
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
-
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
-
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Trading Information
- Previous Close Price
- $0.53
- Day Range
- $0.52–0.56
- 52-Week Range
- $0.13–3.34
- Bid/Ask
- $0.53 / $0.56
- Market Cap
- $36.53 Mil
- Volume/Avg
- 266,201 / 966,103
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.brainstorm-cell.com
Comparables
Valuation
|
Metric
|
BCLI
|
KROS
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.55 | 1.50 |
Price/Sales | — | — | 441.50 |
Price/Cash Flow | — | — | — |
Price/Earnings
BCLI
KROS
PLRX
Financial Strength
|
Metric
|
BCLI
|
KROS
|
PLRX
|
|---|---|---|---|
Quick Ratio | 0.17 | 13.63 | 17.43 |
Current Ratio | 0.24 | 14.25 | 17.72 |
Interest Coverage | −37.46 | — | −145.34 |
Quick Ratio
BCLI
KROS
PLRX
Profitability
|
Metric
|
BCLI
|
KROS
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −319.09% | −35.62% | −22.68% |
Return on Equity (Normalized) | — | −39.15% | −24.50% |
Return on Invested Capital (Normalized) | — | −41.95% | −28.46% |
Return on Assets
BCLI
KROS
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vyybknhxw | Zrjts | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nllkvpz | Lrxqgjg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kxkhhddt | Cdxyp | $97.8 Bil | |
MRNA
| Moderna Inc | Tdjcjxf | Wbyfm | $41.3 Bil | |
ARGX
| argenx SE ADR | Rfprscy | Jysm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fpzjsthn | Mbym | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qhpgxzrt | Vtjkrl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bgmjnvkw | Scjlw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ydzzyttg | Hzdgmg | $12.5 Bil | |
INCY
| Incyte Corp | Znvmchflf | Hwyjjd | $11.6 Bil |